SOUTHERN ENGLAND
Southern England’s Influence in Global Life Sciences Advancements
Southern England is a vastly important region for the health and life sciences sector. It has the highest rate of employees in the UK’s life sciences industry at over 50% across the sub-regions, with the South East of England having the highest share at 24%.1 The area has four of the world’s top ten universities,
nineteen of the top twenty global pharmaceutical companies and world class research centres including the Francis Crick Institute, the Harwell Campus Oxford, and the Sanger Institute Cambridge. In 2021, the South East generated the UK’s highest
share of life sciences industry turnover, at 30% (or £28.6 billion).2
The region is home to the ‘golden triangle’; the
world-leading life sciences cluster of London, Oxford, Cambridge, and the greater South East. These clusters are the most productive in Europe and compete internationally. Specialisms include MedTtech, pharmaceuticals, genomics, biodata, diagnostics, digital health and biomedical engineering. It also has the highest global concentration of world-class research and innovation assets, from science parks, businesses, incubators to healthcare providers, industry players and research centres, including the world-leading Jenner Institute and the national Vaccine Manufacturing & Innovation Centre. We are working with a number of innovative life
sciences companies across the region, including P3 Medical, based in Bristol, South-West of England. The company specialises in the development and manufacture of innovative single-use medical devices. We have been working with their adviser to expand their business into Japan, and anticipate a substantial increase in potential sales value, projected to grow by five times over the coming years. P3 Medical’s success in expanding into Japan not only strengthens their market position but also reinforces their commitment to improving patient care globally. Dafydd Talbot, Business Development Manager of P3 Medical said about the Department’s support: “The support from the Department for Business
12 UKHEALTHCARE P A VILION. COM
and Trade was a huge step for us in getting out to a customer base we wouldn’t have otherwise.” Some of the region’s other specific strengths include: n The largest cell and gene therapy cluster in Europe, and third largest globally, in Stevenage, Hertfordshire.3 n The MedTech Accelerator has been set up in the East of England to facilitate the early-stage development of innovations in the broad area of medical technology that meet unmet clinical needs within the NHS. The Medtech Accelerator supports and finances projects at an early stage to maximise the potential for success in bringing new life enhancing technologies to patients.4
n Launched in 2012, the UK-wide 100,000 Genomes Project sequenced 100,000 genomes in four years; an immensely ambitious project that has never been done on this scale anywhere in the world. Five of the eleven genomic medicine centres are located in London, Oxford, and Cambridge.5
References 1,2
https://www.gov.uk/government/statistics/ bioscience-and-health-technology-sector- statistics-2021/bioscience-and-health- technology-sector-statistics-2021#variation- across-the-uk
3
https://www.great.gov.uk/international/content/ investment/opportunities/cell-and-gene-therapy- in-hertfordshire/
4
http://www.medtechaccelerator.co.uk/ 5
https://www.genomicsengland.co.uk/
MEDICA 2023
Lab Cell and Gene Therapy Catapult
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
